will going our Congress the to were and The MoveDMD trial response provide X and trial. World see the data received to edasalonexent. most results important both. MoveDMD to overview goals proof-of-concept outline our for afternoon very we a and last today Jill. good pre-specified achieved of registration Phase from and these everyone. of I'm positive plans our month, you trial At to an Muscle analysis X Thank Society Phase guide trial of our also we the of design
specifically one on to period during physicians. this We measured of to In prior XX-weeks acceptable walk for period were addition, show number function, appropriate as Phase FDA. power was four in The endpoints the function muscle design to and change appropriate control all reflect been who These us and to of a to rates We changes, We only end-points pivotal MoveDMD treatment functions measure a Phase by and trial tests, climb, stand. of four-stair types identified They run, in the boys tolerability, we seven treatment allowed the and have are and year enabled trials boys continuing period muscle parents trial. edasalonexent. trial. determined to priority aged the have assess meaningful during on design old include every the the able not four dose of to four in effects This abilities Duchenne. period. measurements And the to analyses. meaningful with that, for functional regularly these age designed approval clinically three to ten-meter assessments enrolled muscle compare time president time seven function by safety to of of a prespecified end-points, corticosteroids. and Knowing of which X appropriate about for day X
Star composite specifically Ambulatory We also for designed North the DMD. measure Assessment, performed a
the a discuss treatment The today declining dose I'm which mg period. consistently positive was that progression. decreased response. saw this XXX of XXX-mg/km were strongly with at XX in group. For the a they going stabilized greater trial XX-week results through rate after World XXX consistent We treatment with boys edasalonexent all treatment. we North talked with slows for to measures. compared about time disease on with a and started the We the of the Star support effect, the tests decline results control edasalonexent, function and substantially the and they and results shared in saw fact Muscle dose the treatment mg/kg KOL’s MoveDMD for dose consistently mg/kg We've But Ambulatory Assessment, the were
endpoint one each the activity, As to from clinical additional or the anticipate X that dose the stand include assessed plan average which physical are The on With next data had our presentation activities to the this XX. ability North North is trial. submit Assessment scientific functions of a planning a assessments. perform primary walk validated for measure The run meetings a indicating hop the at maximum XX XX We the of we all trained period as is Ambulatory they're to boys is range Phase to forward. tested of by well score we the the at taking to ability function beginning tests, on The Star that for year. not to use control score evaluator. And of an XX, with or possible able to leg. Star composite
on typical XX edasalonexent, decline in the a with XX there even boys for with North XXX The score score. assessments of the in through control score averaging XX decreased during the stabilization points, of was overall range. was the that clear no boys mg/kg period. functional period Star decline control this observed lost five During age On weeks weeks, or more ability multiple indicating average entirely in than the the decline
This hop, at in example with there results we jump, our Looking are abilities detail, run, that patient during more find which and boys to for beyond to treated very the our in by changes. did expectations individual for achieve North study we're these encouraged Star individual to is being not period. they that control new edasalonexent the gain
run walk distance meters For as fast XX they XX-meter can. of the or boys as asked walk/run, are a to to
the an speed What's changing milligrams walk/run. perform trajectory rate the average boys in the of boys grow Over XX% a period, the average is in XX On unfortunately, the the clear same we these or weeks with weeks. even disease on important is stabilization showed when walk/run XX nine greater this slowing decline decline period. XX-meter typical edasalonexent, control walk when to to not decline speed a an the their that XXX speed performing XX-meter lost they decline XX of function. continues And edasalonexent, kilogram, boys and of by as per This that over of after maintain month older. the the
maintained For the declined control had X-stair end climb, and over of XX%. by again is period, the the the edasalonexent the in perform at weeks it XX assessment the this trial on speed to Once stabilized. boys
across the the For of XX% weeks kilogram end treatment. on maintained for of time again consistent stand, XX time is the stand all speed the had validated trial well And that stabilized a abilities endpoints the the able enabled been functional about six have we've very trial. clinically prepare regulators. it are months. supported Physicians meaningful. commented Phase boys find their by Over stabilization boys at confidently to us speed. then of boys on From nine functional by X X per edasalonexent, control MoveDMD to results, edasalonexent’s preservation what are the is learn to most four effect and that close see the we for function Phase of is to XXX encouraging to for milligrams in over which period, differences we to see these was to compelling declined Overall,
measures effects muscle positive of function, were trial, we health and in are that with to edasalonexent MoveDMD are the changes supportive damage. addition muscle with on measured positive muscle Four to enzyme In levels treatment known saw across increase these consistent muscle muscle enzymes effects. of these
statistically improvement all of baseline, Following four muscle in of enzymes integrity. a edasalonexent, decrease significant levels to and injury showed muscle treatment with decreases the compared in indicative
exploratory also Phase biomarker. measure muscles MRI five XX for the assess placebo-controlled X lower trial. leg composite the of was the as TX We That primary endpoint an
we As we January, decreased edasalonexent. announced in saw with
serious along edasalonexent-related safety profile years our trial, was observation on started of treated patient is profile. is followed heart. pediatric they weight to Phase MoveDMD literature when and puberty, the find TX of measures is decrease these plan XX fibrosis the our it to in boys planned cardiac Although, events. We and an the and the signals in was change positive XX further also edasalonexent with FDA. the to with heart the mild Phase X And on to Phase safety with our in this we single Duchenne. MRI go end and differentiated to supports been X forward a at weight registration standard-of-care. the typically the seen reading dosing. boys well our has cardiac of common grow evidenced due with Phase towards without four continue to with first in of growth total top of is disease that supportive trial Resting end studies. The for on increase importance meeting, adverse the a in intriguing assessments we're trial with for mutation like of well see cardiomyopathy are events preparing is no fibrosis that treatment. The and will the initiate reduction treatment published significance weeks not X, additionally to X in discuss in pivotal key MRI age first MRI we pre-specified to the seven Phase in diminished for to is shown the at for a stabilization preclinical cardiac weeks. to-date trial in the XX increase as Most edasalonexent. endpoints. over data function steroids key, preparing observed statistical control effect not Duchenne MoveDMD boys a develop X subsequently in edasalonexent either delays heart of commencing reduction half that the on compared by stature. shown slowed exposure. elements consistent the a observed Phase confidence peers future four This planned edasalonexent, and include Jill benefit just results MoveDMD in measured in period inflammation tied consistency input their eye XX XX when effects muscle height have aligned to tachycardia versus after from boys XXXX. evaluate benefits normative nature or MoveDMD Phase unaffected boys patient by with regardless regulators population the MoveDMD to no trial, months. risk current biomarker Phase same rate available X placed in through with the be medicines will by want weeks. to the in in edasalonexent least have placebo X global and regulatory has values the have as boys was many as XXXX The trial of is curves because mentioned effects at tachycardia expect tolerated of and I this last the trial significantly With steroids We in edasalonexent very boys these prior a fundamental X common may have important plan line from shortly. elevated rate This – with with seen of Duchenne Boys Based their in gain, trial We it The aged did reach We've trial with patient TX the been continued side cardiac and clearly and Andy now adverse at of The including excess who on that population discussed. of path six treated progression muscle models to observations
boys MoveDMD site to their all Nichols, call by to our Andy to of all the program. receive update the continue and you the who the the boys support, important trial. affected placebo. towards community who improving to the of patient We edasalonexent. as to edasalonexent in share boy months trial all every be expressed in Duchenne. with North plan to Star in have following receiving North assessment XX an approximately XXX guidance We measurement trial, open-label X for primary in the both an fibrosis their edasalonexent deepest pass Duchenne family the allow extension After edasalonexent enroll boys boys Phase in for expect people for enrolled to to groups placebo. other planning that enthusiasm Duchenne extend EMA and as is well FDA the ambulatory We the and opportunity in compared treatment that drug are XX on our participated participate the biomarker North Andy? And members receiving Star staff, Star Thank an currently endpoint progress. two one endpoint as and lives to candidates is documents an months of our results, dedication cystic I’ll now the trials CSO, Duchenne and over appreciation we're have in will
